Destiny Pharma


Market Cap£14m

Last Close 32.5p

Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobial agents that have unique properties that improve outcomes for patients. Destiny’s first product, XF-73, is in a US Phase IIb clinical study.

More Destiny Pharma content >

Investment summary

Destiny Pharma is a virtual UK antimicrobial discovery company in a Phase IIb clinical study in the US. Destiny’s XF series of antimicrobial agents are novel, rapidly bactericidal and not associated with bacterial resistance, which typically limits the use of other antimicrobial agents. This makes Destiny’s lead product, XF-73, ideal for the prevention of post-operative staphylococcal infections, an indication in which no other drugs have been approved. The activity of the XF-series against resistant bacteria may also have utility in the treatment of infections with a biofilm component like cystic fibrosis. We forecast Destiny’s cash reach into 2021, with Phase IIb results for XF-73 in H121.

Y/E Dec
Revenue (£m)
PBT (£m)
EPS (fd) (p)
P/E (x)
P/CF (x)
2018A 0.0 (5.3) (6.0) (11.86) N/A N/A
2019A 0.3 (5.4) (5.5) (10.77) N/A N/A
2020E 0.0 (4.7) (4.6) (8.31) N/A N/A
2021E 0.0 (6.1) (6.1) (12.32) N/A N/A
Industry outlook

While there are valid commercial criticisms of antibiotic development, the growing problem of antimicrobial resistance is making non-dilutive and alternative funding methods available to make antimicrobial drug development easier on companies. In addition, resistance has not been observed against Destiny’s agents and their new preventative indications make antibiotic stewardship less of an issue.

Last updated on 20/07/2020
Content on Destiny Pharma
Destiny Pharma – XF-73 enrolment paused by COVID-19
Healthcare | research Update | 6 May 2020
Destiny Pharma – Eyes on the Phase IIb prize
Healthcare | research Outlook | 10 December 2019
Destiny Pharma (DEST); positive phase 1 results published
Healthcare | Edison Sparks | 16 October 2019
Target Healthcare REIT (THRL); NAV total return of 2.3% for the quarter
View more
Register to receive research on Destiny Pharma as it is published
Share price graph
Balance sheet
Forecast net cash (£m) 4.1
Forecast gearing ratio (%) N/A
Price performance
Actual (17.7) (8.5) (52.2)
Relative* (17.1) (15.3) (43.4)
52-week high/low 68.0p/31.5p
*% relative to local index
Key management
Neil Clark CEO
Shaun Claydon CFO
Dr. William Love Founder and Chief Scientific Officer